BPI Adjuvant Immunization for Th1 and Cytotoxic T Cell Activation

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Current adjuvants used in vaccination often induce unfavorable Th2 responses or have toxic potential, failing to effectively stimulate Th1, Th17, and cytotoxic T cell responses necessary for protection against intracellular pathogens and cancer.

Innovation Solution

Utilizing bactericidal/permeability-increasing protein (BPI) as an adjuvant to stimulate antigen-presenting cells, particularly dendritic cells, to induce Th1, Th17, and cytotoxic T cell responses, potentially in combination with immunomodulatory agents like TLR ligands.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Quantity of substance

If aluminum salts are used as adjuvants, then humoral response is enhanced, but Th1-mediated immune response is insufficient

Engineering Contradiction:

Improveantibody productionVSAvoidTh1 immune response efficacy

Core Design Contradiction:

Quantity of substanceVSReliability

Solution Approach 1:

The patent changes the chemical and functional parameters of the adjuvant from aluminum salts to BPI protein, which has different immunomodulatory properties. BPI preferentially activates Th1, Th17, and cytotoxic T cell responses while maintaining antigen presentation capabilities, thus resolving the contradiction between humoral response enhancement and Th1 response insufficiency

Inventive Principle:

Principle #35Parameter changes

Solution Approach 2:

The patent uses recombinant BPI protein as a model system to replicate and study the immunomodulatory effects of natural BPI. This recombinant copy allows for controlled experimentation and optimization of Th1-inducing adjuvant properties without the limitations of natural source variability

Inventive Principle:

Principle #26Copying

2Power

If conventional adjuvants are used to stimulate immune response, then immune activation is enhanced, but toxic potential increases

Engineering Contradiction:

Improveimmune stimulation strengthVSAvoidtoxicity

Core Design Contradiction:

PowerVSObject-affected harmful factors

Solution Approach 1:

The patent converts the bactericidal activity of BPI, which normally targets Gram-negative bacteria, into a beneficial immunomodulatory effect. The protein's natural ability to interact with bacterial components is harnessed to selectively activate antigen-presenting cells and induce protective immune responses without the toxic side effects of conventional adjuvants

Inventive Principle:

Principle #22Blessing in disguise (Convert harm into benefit)

Solution Approach 2:

BPI acts as an intermediary molecule that bridges the gap between antigen and immune system activation. It selectively binds to and activates antigen-presenting cells through specific receptors, providing a controlled and targeted immune stimulation mechanism that reduces off-target toxicity while maintaining high immunogenicity

Inventive Principle:

Principle #24Intermediary (Mediator)

3Quantity of substance

If adjuvants are used to boost immune response, then cytokine production is increased, but side effects from non-antigen-presenting cell stimulation increase

Engineering Contradiction:

Improvecytokine productionVSAvoidside effects

Core Design Contradiction:

Quantity of substanceVSObject-generated harmful factors

Solution Approach 1:

The patent applies the principle of local quality by enabling BPI to selectively interact with antigen-presenting cells through specific surface receptors. This localized and targeted activation ensures that cytokine production is concentrated in the relevant immune cell population, avoiding widespread stimulation of non-target cells and reducing systemic side effects

Inventive Principle:

Principle #3Local quality

Data Source

PatentUS12527862B2Bactericidal/permeability increasing protein for use in a method of immunization, preferably as an adjuvant in a method of vaccination

Publication Date: 2026.01.20 UNIVERSITY OF REGENSBURG

AI summary

The present invention relates to bactericidal/permeability increasing protein (BPI) for use in a method of immunization of a patient, preferably as an adjuvant in a method of vaccination. The present invention also relates to a preparation comprising BPI for use in a method of immunization of a patient, and optionally an immunomodulatory agent. The present invention further relates to a process of producing a preparation including BPI for use in a method of immunization of a patient.